
|Videos|August 26, 2021
5-Year Follow-Up Data For CPX-351 in AML
Alexandra S. Wolff, PharmD, BCOP, explores the 5-year follow-up data from the phase 3 trial of CPX-351 in AML.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Experimental Multistage Malaria Vaccine Demonstrates Promising Protection in Early Trial
2
Reimagining Pharmacy: A Call to Action for Pharmacy Professionals
3
FDA Approves Milestone Oral Therapy for Adults With Thalassemia Anemia
4
Stress Signals Drive Cardiovascular Disease Risk in Patients With Depression, Anxiety
5










































































































































































































